An assessment of the expression of key OXPHOS subunit proteins (succinate dehydrogenase B [SDHB], Ubiquinol-Cytochrome C Reductase Core Protein 2 [UQCRC2], Mitochondrially Encoded Cytochrome C Oxidase I [MTCO1], ATP synthase subunit alpha of complex V [vATP5A]), revealed no change in the protein content with NR co-treatment, suggesting the improved mitochondrial respiration rates observed are likely related to mitochondrial functional capacity improvements rather than mitochondrial content improvements (Fig 2HL)
Healthcare provider can assess the nature of the abdominal pain, inquire about any other symptoms you may be experiencing, and conduct a thorough evaluation to determine the underlying cause
The enhanced efficacy profile potentially reduces treatment duration and improves patient compliance, translating to better therapeutic value propositions
IGFBP Interactions Tomas et al
Initially, the research focused on treating diabetes and cardiovascular diseases (9,10,17,18)